Clinical trials: Dose Response Relationship, Drug
HIV Infections
A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients
To determine the maximum tolerated dose of CI-1012 in late-stage HIV-1-infected patients. To determine the antiretroviral activity of CI-1012 when added to combination therapy.
- Trial name
- NCT00002218
- Testing
- CI-1012
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Parke-Davis
HIV Infections
A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
The purpose of this study is to determine the safety of anti-HIV drugs combined with low-dose chemotherapy (consisting of cyclophosphamide [CTX]) in HIV-positive patients.
- Trial name
- NCT00000899
- Testing
- Nelfinavir mesylate, Lamivudine, Filgrastim
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients
To determine the safety and effectiveness of treatment with ribavirin (RBV) plus isoprinosine (INPX) in preventing the development of AIDS in patients infected with the AIDS virus (HIV).
- Trial name
- NCT00000699
- Testing
- Inosine pranobex, Ribavirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease
To determine the toxicity of low dose foscarnet administered for 4 weeks to HIV infected patients who are asymptomatic, have AIDS, or other HIV associated conditions and a CD4+ lymphocyte count < 500 cells/mm3.
- Trial name
- NCT00000729
- Testing
- Foscarnet sodium
- Where
- 11 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.
To evaluate the long-term safety and effectiveness of the drug 2',3'-dideoxycytidine ( zalcitabine; ddC ) in treating patients with AIDS or advanced AIDS related complex ( ARC ).
- Trial name
- NCT00000704
- Testing
- Zalcitabine
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cardiac Toxicity, Lymphoma
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002827
- Testing
- bleomycin sulfate, filgrastim, dexrazoxane hydrochloride
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 294 people
- Sponsor
- Children's Oncology Group
HIV Infections
Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children
The purpose of this study is to see if PEG-Intron is safe and tolerated when given to children, to see how much gets into the blood and how long it stays in the blood, and to see how well it works to reduce viral load (level of…
- Trial name
- NCT00006325
- Testing
- Peginterferon alfa-2b
- Where
- 15 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
To evaluate the safety of single and multiple doses (28 daily doses) of 9-[2-(R)-[[bis[[(isopropoxycarbonyl)- oxy]methoxy]phosphinoyl]methoxy]propyl]adenine fumarate (PMPA) prodrug administered orally to HIV-infected patients.
- Trial name
- NCT00002396
- Testing
- Tenofovir disoproxil fumarate
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
HIV Infections, HIV Seronegativity
Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection
The purpose of this study is to see if an HIV vaccine, AIDSVAX B/B, can protect adults who are at risk from becoming infected with HIV.
- Trial name
- NCT00002441
- Testing
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
- Where
- 67 sites in United States, Canada and 2 more
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- VaxGen
Pneumonia, Pneumocystis Carinii, HIV Infections
The Safety and Effectiveness of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Who Have Had PCP Before
To evaluate and compare the safety, tolerability, and efficacy of biweekly administration of 1 of 3 doses of aerosol pentamidine when used as a prophylactic agent in patients who have recovered from their first episode of…
- Trial name
- NCT00002291
- Testing
- Pentamidine isethionate
- Where
- United States
- Sponsor
- Fisons
HIV Infections
The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
The purpose of this study is to evaluate the safety and tolerability of giving IL-2 plus anti-HIV (antiretroviral) therapy to HIV-positive patients with CD4 cell counts (cells of the immune system that fight infection) of at…
- Trial name
- NCT00000825
- Testing
- Aldesleukin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
PanACEA Sutezolid Dose-finding and Combination Evaluation
This study is an open-label, randomized, controlled, multi-center Phase IIB dose-finding trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response-relationship of different doses of sutezolid (STZ) in…
- Trial name
- SUDOCU (NCT03959566)
- Testing
- Sutezolid, Bedaquiline, Delamanid, Moxifloxacin, Midazolam oral solution
- Where
- 4 sites in South Africa, Tanzania
- Volunteers
- 75 people
- Sponsor
- Michael Hoelscher
X-linked Hypophosphatemia (XLH)
Effective Dosing of Burosumab in XLH
X-linked hypophosphataemia (XLH) is a rare, hereditary condition. The genetic defect leads to low blood phosphate levels and vitamin D suppression. Phosphate is required for strong bones and teeth and to store energy in cells.
- Trial name
- NCT07183579
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- University of Nottingham
HIV Infections
A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes
To study the tolerance and safety of increasing doses of AL-721 in patients with persistent generalized lymphadenopathy (PGL) and symptomatic HIV infection, and to obtain preliminary information on the effectiveness of AL-721…
- Trial name
- NCT00001012
- Testing
- AL 721
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Melanoma, Neoplasm Metastasis
ADI-PEG in Patients With Metastatic Melanoma
This is a study to determine the safety and toxicity of increasing doses of arginine deiminase combined to polyethylene glycol (ADI-PEG) in patients with nonresectable metastatic melanoma.
- Trial name
- NCT00029900
- Testing
- ADI PEG
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- FDA Office of Orphan Products Development
HIV Infections, Hepatitis C
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
This study will test the safety and effectiveness of a new treatment for hepatitis C (HCV) in patients who also have HIV. The usual treatment for HCV in people who are not HIV-infected is interferon-alfa (IFN) with ribavirin…
- Trial name
- NCT00015652
- Testing
- Ribavirin, Aldesleukin, Peginterferon alfa-2b
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults
The purpose of this study is to compare the safety and effectiveness of 9 doses of HU in order to find the best dose of HU to use with ddI and d4T in fighting HIV infection.
- Trial name
- NCT00002427
- Testing
- Hydroxyurea, Stavudine, Didanosine
- Where
- 18 sites in United States
- Volunteers
- 225 people
- Sponsor
- Research Institute for Genetic and Human Therapy
Aged, Drug
The Effect of Age on the Median Effective Dose (ED50) of Intranasal Dexmedetomidine for Rescue Sedation Following Failed Sedation With Oral Chloral Hydrate During Magnetic Resonance Imaging
Increasing evidences suggest that dexmedetomidine Pharmacokinetic are different in children. We performed a up-down sequential allocation study to determine the ED50 for rescue sedation following sedation failures in children and…
- Conditions
- Aged, Drug, Dose-Response Relationship
- Trial name
- NCT02253199
- Testing
- intranasal dexmedetomidine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangzhou Women and Children's Medical Center
HIV Infections
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems
The purpose of this study is to determine the safety of a drug called interleukin-2 (IL-2) given with anti-HIV therapy in children with HIV infection. This study will also determine the best dose of IL-2 to give children.
- Trial name
- NCT00006066
- Testing
- Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 92 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Nicotine Dependence, Drug Abuse
Effects of Nicotine on Brain Activity as Measured by fMRI
Background: Nicotine addiction is common among people who smoke tobacco, and the addictive properties of nicotine make smoking cessation difficult even for people who want to quit.
- Trial name
- NCT01037153
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)